However, the development of novel antibody–drug conjugates has introduced a new treatment pathway for HER2-low breast cancers, a subset of HER2-negative patients constituting around 50% of the breast cancer population, which improves the overall survival of HER2-low patients [6]. This evidence concerns the gene ERBB2 and breast carcinoma.